Shanghai OPM Biosciences Co., Ltd. (SHA:688293)
53.95
+2.95 (5.78%)
At close: Jul 15, 2026
Shanghai OPM Biosciences Revenue
Shanghai OPM Biosciences had revenue of 182.16M CNY in the quarter ending March 31, 2026, with 117.68% growth. This brings the company's revenue in the last twelve months to 453.39M, up 50.52% year-over-year. In the year 2025, Shanghai OPM Biosciences had annual revenue of 354.91M with 19.40% growth.
Revenue (ttm)
453.39M
Revenue Growth
+50.52%
P/S Ratio
15.67
Revenue / Employee
1.24M
Employees
367
Market Cap
7.10B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 354.91M | 57.67M | 19.40% |
| Dec 31, 2024 | 297.24M | 54.12M | 22.26% |
| Dec 31, 2023 | 243.12M | -51.24M | -17.41% |
| Dec 31, 2022 | 294.37M | 81.68M | 38.41% |
| Dec 31, 2021 | 212.68M | 87.71M | 70.19% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Star Lake Bioscience Co., Inc.Zhaoqing Guangdong | 15.60B |
| Youcare Pharmaceutical Group | 2.42B |
| China Resources Boya Bio-pharmaceutical Group Co.,Ltd | 1.84B |
| Xiangxue Pharmaceutical | 1.53B |
| Chengdu Kanghua Biological Products | 1.20B |
| Wuhan Keqian Biology Co.,Ltd | 932.09M |
| Zhejiang Ausun Pharmaceutical | 794.80M |
| Daan Gene | 737.96M |